an update of knowledge for pd-l1 in head and neck cancers
Published 4 years ago • 132 plays • Length 2:35Download video MP4
Download video MP3
Similar videos
-
26:30
head and neck cancer treatment update: pembrolizumab, nivolumab and pd-l1 markers
-
3:13
pd-l1 and alternative biomarkers in head and neck cancer
-
2:31
low or negative pd-l1 head and neck cancertreatment options for patients - hpv advances
-
1:18
dr. joel neal on impact of pd-l1 tests on pembrolizumab, nivolumab efficacy in frontline nsclc
-
1:57
pd-l1 as a prognostic factor in gastric cancer patients
-
2:19
elucidating novel biomarkers for head and neck cancers
-
5:38
targeting sort1 positive cancers
-
2:05
updates in head and neck cancers: 2023 west oncology
-
0:43
predicting treatment outcomes in head and neck cancers with biomarkers
-
6:39
latest developments in oral cancer treatment: pdl-1 inhibitors
-
2:07
dr. weiss on biomarkers in head and neck cancer
-
15:39
head and neck cancer [1 of 3] - penn state hershey cancer institute
-
1:00
dr. lee on combining anti-pd-l1 to standard of care for head and neck cancer
-
2:19
therapeutic advances in immune checkpoint inhibitors for head and neck cancers
-
10:09
diagnosis, staging, and prognosis
-
1:02
dr. topalian on evolution of pd-1/pd-l1 agents in oncology
-
6:21
the emergence of pd-l1 inhibitors
-
8:59
head and neck cancer: ask dr. bruce davidson
-
6:38
efficacy of pd-l1 inhibitor avelumab in nepc/avpc